Propanc Biopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Propanc Biopharma generated cash of -$935,118, which is more than the previous year. Cash used in financing activities reached the amount of $941,894 last year. Net change in cash is therefore $11,038.
Cash Flow
| 2015 | -1.42M | -5.58K | 1.28M |
|---|---|---|---|
| 2016 | -4.49M | -12.06K | 4.53M |
| 2017 | -2.05M | 0 | 2.09M |
| 2018 | -2.17M | 0 | 2.39M |
| 2019 | -2.06M | -2.87K | 2.11M |
| 2020 | -1.84M | 0 | 1.89M |
| 2021 | -1.14M | 0 | 1.05M |
| 2022 | -1.43M | 0 | 1.49M |
| 2023 | -1.10M | 0 | 1.11M |
| 2024 | -935.11K | 0 | 941.89K |
PPCB Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 10.04K | 4.06K | 2.25K | 67.00K | 2.39K | 19.92K | 69.04K | 121.07K | 107.62K | 87.79K |
Operating activities | ||||||||||
Net income | -1.82M | -2.66M | -2.65M | -2.02M | -4.74M | -5.75M | -7.03M | -7.86M | -9.41M | -3.41M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 21.65K | 22.93K | 5.67K | 1.99K | 2.47K | 2.30K | 2.22K | 2.16K | 877 | 81 |
Stock-based compensation expense | 0 | 141.35K | 387.13K | 82.87K | 300.41K | 245.14K | 646 | 1.68M | 1.72M | 277.85K |
| Deferred income tax benefit | 0 | 141.35K | 387.13K | 82.87K | 300.41K | 245.14K | 646 | 1.68M | 1.72M | 277.85K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -610 | 1.66K | -2.14K | 3.33K | 489 | 1.63K | 21.95K | -17.80K | 0 |
Inventories | 0 | 610 | -1.66K | 2.14K | -3.33K | -489 | 0 | 0 | 0 | 0 |
Accounts payable | 242.40K | 80.97K | 18.87K | 178.31K | -59.73K | -164.92K | 732.79K | 147.95K | 139.20K | -47.97K |
Cash generated by operating activities | -935.11K | -1.10M | -1.43M | -1.14M | -1.84M | -2.06M | -2.17M | -2.05M | -4.49M | -1.42M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.18K | 0 |
Investments In Property Plant And Equipment | -1 | 0 | 0 | 0 | 0 | -2.87K | 0 | 0 | -9.87K | -3.90K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | -2.87K | 0 | 0 | -12.06K | -5.58K |
Financing activities | ||||||||||
Common Stock Issued | 23.05K | 24.71K | 99.28K | 776.04K | 450K | 1.10M | 0 | 0 | 767.56K | 29K |
Payments for dividends | 0 | -466.27K | -700.34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -776.04K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 224.88K | 590.25K | 766.5K | -43K | -1.46M | 1.09M | -491.26K | 1.63M | -425.50K | 1.28M |
Cash used in financing activities | 941.89K | 1.11M | 1.49M | 1.05M | 1.89M | 2.11M | 2.39M | 2.09M | 4.53M | 1.28M |
Net Change In Cash | 11.03K | 5.98K | 1.81K | -64.75K | 64.61K | -17.52K | -49.12K | -52.02K | 13.44K | 19.82K |
Cash at end of period | 21.08K | 10.04K | 4.06K | 2.25K | 67.00K | 2.39K | 19.92K | 69.04K | 121.07K | 107.62K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |